Tradestie Institutional Equity Comparison Engine

APUS vs ONEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

APUS Overall Edge

APUS Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Apimeds Pharmaceuticals US, Inc. (APUS) driven by superior Growth & Margin, Momentum & Technical while ONEN counters with relative strength in Options & Structure. Fundamentally, APUS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ONEN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, APUS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ONEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
APUS N/M vs ONEN N/M Fwd P/E
Growth & Margin Winner APUS
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner APUS
1Y -15.8% vs -84.7% ยท 52W Pos 11% vs 2%
Options & Structure Winner ONEN
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
APUS NYSE American
Apimeds Pharmaceuticals US, Inc.
Pharmaceutical Preparations
$1.60
-8.05% 1D
Market Cap $3.2M
1M Return -49.37%
1Y Return -15.79%
Forward P/E N/M
Unified AI Score
44.9 / 100 HOLD
Tech 35.0 Fund 43.0 Flow 50.0 Mom 55.0
ONEN US Equity
ONEN
Institutional Equity
$0.53
+9.8% 1D
Market Cap N/A
1M Return -59.53%
1Y Return -84.72%
Forward P/E N/M
Unified AI Score
48.8 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: APUS -15.79% ONEN -84.72% Spread: +17.24 pp (APUS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
APUS TTM Op. Margin: 0.0% ONEN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on APUS vs ONEN. Trailing 12-month operating profitability (APUS 0.0% vs ONEN N/A) and valuation multiples (APUS N/M vs ONEN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: APUS (7) vs ONEN (1)
Institutional Metric APUS ONEN Criterion Row Winner
Market Capitalization Scale $3.2M N/A Larger Scale APUS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth APUS
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin APUS
Net Profit Margin Profitability 0.0% N/A Higher Margin APUS
Return on Equity (ROE) Capital Efficiency 0.0% N/A Higher ROE APUS
52-Week Range Position Momentum 11% ($1โ€“$10) 2% ($0โ€“$4) Stronger Trend APUS
Beta / 30D Volatility Risk Regime 3.20ฮฒ ยท 72% Vol -0.18ฮฒ ยท 201% Vol Lower Realized Risk APUS
Unified Institutional Score Composite Signal 44.9 / 100 (HOLD) 48.8 / 100 (HOLD) Higher Composite ONEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full APUS vs ONEN Buy Guide
APUS BREAKDOWN
80d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live APUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ONEN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ONEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither APUS nor ONEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.